Topic: Placebo Trials

Dr. Marcy Bowers, president of the World Professional Association for Transgender Health (WPATH), defended gender-affirming care by claiming trans identities have existed since "antiquity." Bowers dismissed the need for "level one" randomized controlled trials, comparing gender transition to cancer treatment where using a placebo would be unethical. The discussion highlights the controversy over WPATH removing age guidelines for surgeries and the lack of consensus-based science in the field.

The long-term clinical trials for COVID-19 vaccines have effectively lost their control groups because most placebo recipients were offered the actual vaccine after the EUA was granted. Dr. Carlos Fierro of Johnson County Clinical Trials confirmed that nearly all volunteers in the Moderna study chose to get the vaccine, leaving no comparison group for ongoing safety monitoring. This development is criticized as a failure of scientific protocol that prevents the assessment of long-term side effects.

COVID-19 vaccine trials are using laboratory-confirmed disease as a primary endpoint, comparing infection rates between vaccinated and placebo groups. Critics point out that these trials often fail to account for variables like mask-wearing or social distancing among participants. Separately, a massive increase in freight train traffic from China suggests that global trade and cargo movement are returning to full capacity.

Dr. Francis Collins, head of the National Institutes of Health (NIH), is leading a massive effort to launch four vaccine trials involving 30,000 volunteers each starting in July 2020. Collins noted that trials must occur in areas where the virus is actively spreading, specifically targeting "red states" that opened early. A reference to "dummy placebos" in his description of the trial methodology raised questions about the terminology used for control groups.